

The GenomeAsia 100K Project enables genetic discoveries across Asia

<https://doi.org/10.1038/s41586-019-1793-z>

GenomeAsia100K Consortium*

Received: 29 January 2018

Accepted: 11 October 2019

Published online: 4 December 2019

Open access

The underrepresentation of non-Europeans in human genetic studies so far has limited the diversity of individuals in genomic datasets and led to reduced medical relevance for a large proportion of the world's population. Population-specific reference genome datasets as well as genome-wide association studies in diverse populations are needed to address this issue. Here we describe the pilot phase of the GenomeAsia 100K Project. This includes a whole-genome sequencing reference dataset from 1,739 individuals of 219 population groups and 64 countries across Asia. We catalogue genetic variation, population structure, disease associations and founder effects. We also explore the use of this dataset in imputation, to facilitate genetic studies in populations across Asia and worldwide.

The underrepresentation of non-European individuals in human genetic studies¹ limits the applicability of the results for a large proportion of the world's population². Reference genome datasets^{3–12} are needed to characterize population-specific variation, enable efficient imputation of variants that are not directly genotyped, and extend genome-wide association studies (GWAS) to additional populations. The value of population-specific reference datasets is well recognized and projects based in the United States and Europe have provided deep characterization of specific populations (for example, Ashkenazi Jews¹² and individuals from the Netherlands³ and Iceland¹³) and, in particular, data from individuals of Nordic countries have provided examples of how reference genome datasets can be used to drive comprehensive genetic studies across an entire population¹⁴. In Africa, populations show complex genetic patterns, smaller blocks of linkage disequilibrium and higher levels of heterozygosity, which provides unique value for genetic studies. Across the continent, early reference genome datasets for diverse populations are being built as part of H3Africa and other studies^{5,15}. A Korean reference genome as well as Japanese and Chinese reference genome datasets have been created, and the formation of large biobanks such as BioBank Japan¹⁶ and the China Kadoorie Biobank¹⁷ will accelerate the pace of discovery of disease associations across east Asia.

A shared recognition of the value of coordinated efforts and the need for reference genome datasets that would be useful for the complex populations of Asia has led to the formation of the GenomeAsia consortium (<http://www.genomeasia100k.com>). The consortium serves to facilitate and coordinate sequencing efforts among consortium members to maximize the value of the genomic sequence data that is produced and to facilitate efforts by national or other regional groups. Here we describe the GenomeAsia Pilot (GAsP) project, which consists of analyses of the whole-genome sequencing data of 1,739 individuals from 219 population groups across Asia, with the ultimate goal of providing a useful genomic resource and facilitating genetic studies in Asia. We use the data that was generated in this pilot to analyse population structure and history, and as the basis for designing larger-scale genomic studies. Furthermore, we explore disease-associated loci as an initial comparison of differences between populations. We show that

the variant data produced by this project improve variant filtering for the discovery of disease-associated genes of rare diseases. We show that Asia has sizable founder populations and that further studies in these populations may be useful for the discovery of rare-disease-associated genes. We also report an initial survey of loss-of-function alleles found in the GAsP project.

The GAsP dataset

For the GAsP project, we generated 1,267 high-coverage (average 36×) whole-genome sequences and analysed these together with 596 publicly available human genome sequences from previous sequencing studies (Supplementary Information 1, 2 and Supplementary Tables 1a–c, 2a). The 1,739 samples were enriched for individuals from population isolates to capture the broadest wealth of genetic diversity; the dataset includes 598 sequences from India, 156 from Malaysia, 152 from South Korea, 113 from Pakistan, 100 from Mongolia, 70 from China, 70 from Papua New Guinea, 68 from Indonesia, 52 from the Philippines, 35 from Japan and 32 from Russia (Fig. 1a–c and Supplementary Table 1a–c). To facilitate comprehensive and comparative analysis of human genetic variation, we included sequencing data from African, European and American samples (Supplementary Table 1a, b). The sequenced samples originate from 7 global regions, 64 different countries of origin and 219 population groups. About 80% of the samples come from Asia and emphasize population groups that are underrepresented in previous genetic studies (Fig. 1a, b, Supplementary Tables 1a–c, 2b and Supplementary Information 1, 2). Each global region and population group was assigned a unique three-letter code for future reference (see Supplementary Table 1a for three-letter code designations). Within Asia, the sampling of many distinct population groups allowed us to analyse the relationship between geography, physical characteristics and genetic variation. In south and southeast Asia, in particular, we sampled across diverse populations to gather new insights into how groupings defined on the basis of caste and language relate to genetic diversity, admixture with extinct hominins and other genetically described characteristics.

*A list of participants and their affiliations appears in the online version of the paper.




Fig. 1 | Sampling distribution of GASP.

a, b, Sample sizes. **c**, Location, language and social hierarchy associated with samples from south Asia. Groups with fewer than three samples are not plotted. See Supplementary Table 1a for definitions and descriptions of samples and population groups included in each geographically defined set.

Population structure

Knowledge of the complex history of Asian populations informs optimal sampling for larger-scale biomedical sequencing efforts. We applied standard approaches for detecting recent positive selection, quantifying the population structure and inferring the history of the different populations, including principal component analysis¹⁸, multiple sequentially Markovian coalescent (MSMC)¹⁹, ADMIXTURE²⁰, F_{ST} , uniparental analyses and the analysis of the Y chromosome and mitochondrial haplogroups (Fig. 2, Extended Data Fig. 1 and Supplementary Information 3–10). Our results generally recapitulate the broad inferences of previous studies, and ADMIXTURE plots show complex structure within south and southeast Asia (Fig. 2a). In particular, India, Malaysia and Indonesia contain multiple ancestral populations as well as multiple admixed groups. On the basis of MSMC cross-coalescence rates, which reflect the increase in coalescence times of haplotypes sampled from different populations relative to haplotypes sampled from the same population¹⁹, we estimate that the oldest population splits in southeast Asia and Oceania involve Melanesians and/or Negritos, who show a substructure from approximately 40 thousand years ago and evidence of separation around 20–30 thousand years ago (Extended Data Fig. 1b and Supplementary Information 3). The population structure provides genetic information on classically defined population groups to aid future studies. For example, using multiple analytical approaches (Supplementary Information 3, 6), we confirmed that the anthropologically classified ‘Negrito’ groups from India, Malaysia and the Philippines, are genetically more closely related to their geographical neighbours than they are to other Negrito groups^{21,22}, suggesting that dark skin colour is probably an environmental adaptation (for example, to high levels of solar radiation) and not an indicator of shared ancestry.

Our dense sampling of Asian populations enables the examination of Denisovan admixture in greater detail than has been previously possible, providing information about population splits or in-flows that occurred at or after the time of admixture (Supplementary Information 10). Our estimates of Denisovan ancestry were highest in Melanesians and the Aeta, intermediate in the Ati and groups from the Indonesian island of Flores, and low (but still significantly greater than 0) in most south, east and southeast Asian populations. We found high levels of Denisovan ancestry in Philippine Negrito groups but not in Malay or Andaman Negritos; these results are qualitatively similar to what was found in a previous study that was based on single-nucleotide polymorphism (SNP) arrays²³. The high levels of Denisovan ancestry in Melanesians and the Aeta are consistent with an admixture event into a population that is ancestral to both²³; however, two lines of evidence suggest that the ancestors of the Aeta experienced a second

Denisovan admixture event. First, multiple analyses found that the Aeta are genetically more similar to populations without appreciable Denisovan ancestry (for example, Igorot, Malay and Malay Negrito groups) than they are to Melanesians (Supplementary Information 3, 6). This can be explained by more recent gene flow from other populations without Denisovan ancestry. However, such gene flow would reduce the levels of Denisovan admixture below that found in Melanesians. More directly, we find that putative Denisovan haplotypes that are unique to the Aeta ($n = 962$) are significantly longer than putative Denisovan haplotypes shared between Aeta and Papuans ($n = 596$, mean = 16.1 kb compared with mean = 14.1 kb, Mann–Whitney U -test, $P < 10^{-10}$), or putative Denisovan haplotypes unique to Papuans ($n = 727$, mean = 16.1 kb compared with mean = 14.9 kb, Mann–Whitney U -test, $P < 10^{-1,000}$) (Supplementary Information 10), supporting a scenario in which a second admixture event between the Aeta and Denisovans happened after the separation of the Aeta and Melanesians. Two distinct Denisovan admixture events are most consistent with *Homo sapiens* and Denisovans interacting within southeast Asia²³, making it likely that admixture occurred within Sundaland (Fig. 2b) or even farther east^{24,25}.

A recent study found a slightly increased amount of Denisovan ancestry in south Asians compared with a priori expectations²⁶. We examined whether this was correlated with either language or social and/or caste status. South Asian samples were grouped into individuals who speak Indo-European languages and individuals who speak non-Indo-European languages (excluding individuals who speak Tibeto-Burman languages), as well as four social or cultural groups: tribal (Adivasi) groups, lower-caste groups, high-caste groups and Pakistani groups (Indo-European language speaking only). We found that the average levels of Denisovan ancestry were significantly different between the four social or cultural groups (Mann–Whitney U -test, $P < 10^{-8}$ for all pairwise comparisons; Fig. 2c and Supplementary Information 10). Our results are consistent with the scenario that Indo-European-speaking migrants who entered the subcontinent from the northwest admixed with an indigenous South Asian (ancestral south Indian)^{27,28} group who had higher levels of Denisovan ancestry.

Medical relevance

We evaluated the use of GASP dataset in disease-associated genetic studies and medically relevant applications to determine how the results of larger continuing GenomeAsia studies can be used to improve human health (Supplementary Table 4a). We annotated high-quality variants using public databases including ExAC (Exome Aggregation Consortium)²⁹, gnomAD²⁹, 1000 Genomes Project⁴, ESP (NHLBI GO Exome Sequencing Project)³⁰ and dbSNP (Extended Data Fig. 2) and focused




Fig. 2 | Population structure and admixture.

a, ADMIXTURE plots for $k=12$ and $k=14$ illustrating the identification of 12 reference groups.

b, Proposed modern human migration route into southeast Asia during the Last Glacial Maximum with potential locations of Denisovan admixture (yellow asterisks). Green indicates the above water landmass at the glacial maximum and white outlines indicate present-day shorelines.

c, Estimates of Denisovan ancestry in south Asians, stratified by social/cultural group and language. IE, Indo-European. Adivasi Indo-European, $n=30$; Adivasi non-Indo-European, $n=196$; caste Indo-European, $n=68$; caste non-Indo-European, $n=155$; upper caste Indo-European, $n=49$; upper caste non-Indo-European, $n=19$; Pakistani Indo-European, $n=79$. The centre line indicates the median; box limits show the middle 50%; whiskers extend two standard deviations from the mean; points are outliers.

on coding-sequence variants. Overall 23% of protein-altering variants in GASp were not found in these data sources. As expected the majority of coding variants were singletons or very rare (Extended Data Fig. 2). However, the absolute numbers of novel variants with a minor allele frequency (MAF) $\geq 0.1\%$ within our pan-Asian dataset is large ($n=194,585$), and these are frequent enough to be of relevance for large-scale genetic association studies. We also searched for variants present at low frequency in the overall dataset that are present at significantly higher allele frequencies in one or more of the population groups. We found an additional 144,329 novel variants with MAF $>1\%$ in the full GASp dataset that were present at a frequency of greater than 1% within populations grouped by geography; South Asia, Southeast Asia, Northeast Asia or Oceania (see Supplementary Table 1a for description of samples and population groups included in each geographically defined set). These geographical regions contain many diverse population groups, and additional studies are needed to characterize patterns of genetic variation in these groups and disease relevance.

In rare disease genetics, databases are used to filter based on allele frequency with the idea that common alleles are unlikely to be responsible for rare highly penetrant disorders; however, in the absence of appropriate population reference datasets, allele frequencies can be misclassified and may lead to false disease associations³¹. We explored whether the GASp variant dataset can improve the ability to identify disease-relevant variants in Asian cohorts. We analysed 152 exomes from individuals participating in the Indian Maturity Onset Diabetes in the Young (MODY) project. When both the gnomAD and GASp datasets were used for filtering (MAF $>0.1\%$), we reduced the set of remaining candidate variants by approximately twofold in comparison to using the gnomAD dataset alone (Fig. 3a). In this process, we identified a common population polymorphism in *NEUROD1* (H241Q) that is probably benign but that was previously reported to be medically relevant^{32,33}. We annotated variants that were identified in the GASp dataset against the Human Gene Mutation Database (HGMD) disease-causing pathological and ClinVar pathogenic variants. This analysis identified 732 variants (686 SNPs and 46 insertions or deletions (indels)) in 514 genes (Fig. 3b, Supplementary Table 4b, c and Supplementary Information 11). We

compared the 732 pathogenic variants against the gnomAD, ExAC²⁹, 1000Genomes⁴, ESP³⁰, dbSNP³⁴, ALSPAC, TwinsUK³⁵ and 1000Japanese⁶ databases to remove variants that occurred at $>1\%$, focused on those with allele frequencies $>0.15\%$ in GASp (38 variants), and reviewed them against the criteria defined by the American College of Medical Genetics (ACMG). This resulted in reclassification of 11 of the 38 variants (Supplementary Table 4d). We examined the geographical distribution of the remaining, revalidated but high-frequency, pathogenic disease-associated variants. As expected, most of these variants were highly enriched in Asia. For example, an HBB variant (chromosome 11: 5248155 c.92+5G>C) associated with β -thalassaemia is found almost exclusively in south Asians and at a lower frequency in southeast Asians (Fig. 3c).

We also examined our dataset for novel variants in genes known to be associated with cancer risk. We found 13 unique variants in 6 genes from 17 samples. This included frameshift, stop-gained and essential splice-site mutations in *BRCA2* ($n=9$), *BRCA1* ($n=1$), *ATM* ($n=2$), *BLM* ($n=1$), *NBN* ($n=2$) and *PMS2* ($n=2$) (Fig. 3d and Supplementary Table 4e). Of the two *PMS2* essential splice variants, one was found in a Korean sample. Loss-of-function mutations in *PMS2* are associated with mismatch repair defects that lead to a higher risk of cancer development. In a separate study of gall bladder cancer, we found the same essential splice site *PMS2* mutation (chromosome 7:6043690C>G) in a Korean patient whose gall bladder cancer exhibits microsatellite instability (E.W.S. and S. Seshagiri, manuscript in preparation). Identification of genetic variants that affect drug efficacy and safety through the alteration of pharmacokinetics enables application of individualized treatment^{36–41}. Variation in drug responses are generally recognized and recommendations for dosing are sometimes guided by apparent or self-reported population identity despite the lack of a rigorous pharmacogenomic basis. We assessed the allele frequencies of key pharmacogenomic variants in our dataset to identify inter-population differences that have potential implications on drug testing and treatment (Fig. 3e, Supplementary Table 4g and Supplementary Information 13).

Carbamazepine, clopidogrel, peginterferon and warfarin showed the largest variation between populations in predicted adverse drug responses with groups ranging from 0 and 100 predicted adverse drug




Fig. 3 | Disease-relevant variant discovery. **a**, Filtering using the GAsP dataset improves candidate variant discovery by removing population specific variants ($n = 152$). The centre line indicates the median; box limits show the upper and lower quartiles; whiskers extend $1.5 \times$ the interquartile range. **b**, Allele count (AC) and frequency distribution of variants in the GAsP dataset that are designated disease-causing in the Human Gene Mutation Database (HGMD) or pathogenic in ClinVar. Autosomal-dominant (AD) or autosomal-recessive (AR) or other (unknown) classification as per OMIM. A number of variants ($n = 37$) that had previously been reported to be pathogenic are found

in the GAsP study dataset at high frequency and were reclassified (Supplementary Table 4d). **c**, Frequency of β -thalassaemia variant (chromosome 11:5248155 c.92+5G>C) across Asia shows a geographical enrichment. MAF in South Asia is 1.4%. NA, not available. **d**, Novel cancer-predisposing variants identified in the GenomeAsia dataset. **e**, Population-specific probabilities of adverse drug reactions predicted from the aggregate allele frequencies of known variants associated with response to the indicated drugs.

responses. For example, the HLA-B*15:02 variant, associated with risk for development of Steven Johnson syndrome³⁸ in patients treated with carbamazepine was found to occur at an increased frequency in Austronesian language-speaking populations from southeast Asia (for example, 63% in the Mentawai of West Sumatra; 46.6% in the Nias of North Sumatra) compared with other groups (Supplementary Information 13). There are roughly 400 million individuals who belong to Austronesian groups that are at increased risk for carbamazepine sensitivity, including the vast majority of the people from Indonesia, Malaysia and the Philippines.

Founder populations

Population bottlenecks produce strong founder effects and increased rates of recessive disease. In populations with strong founder effects, the loss-of-function variant frequency spectrum is skewed higher, greatly increasing power of association⁴² and providing unique advantages for the identification of genes associated with both rare and complex diseases^{43,44}. We followed the approach described in a previous study on south Asian populations to characterize the degree to which genomic segments are inherited as identical by descent (IBD) in population groups in our dataset⁴⁵.

Our analysis revealed IBD scores of 1.465 and 0.817 for Finnish and British groups, consistent with previous analyses⁴⁵. The IBD score of all of the groups was normalized relative to the Finnish group (Fig. 4a and Supplementary Information 12). Our study includes many groups with small population sizes and it is expected that endogamy paired with small population size will greatly increase IBD scores. We found that indigenous and tribal groups had IBD scores that were skewed upwards from non-tribal groups (Fig. 4b). Notably, we found that a number of Asian groups with large urban populations have IBD scores above or close to that of the Finnish population. For example, samples from an outpatient hospital in Chennai, a city with a census size of 9 million, had an IBD score that was approximately 1.3 times greater than the score for the Finnish group.

Human knockouts

Homozygous loss-of-function alleles found in humans give us the opportunity to assess the phenotypic effect of specific gene loss and can provide important information about opportunities for treating disease^{46,47}. To assess the contents of our dataset, we examined high-confidence protein-truncating variants (PTVs). We found 17,566 PTVs with at least 1 PTV in approximately 43% of all protein-coding genes ($n = 8,766$; Fig. 4c). Among the PTVs, most were heterozygous variants




Fig. 4 | Founder effects and homozygous loss of function. **a**, IBD scores across different population groups are shown for 96 ethnicities (1,417 samples) across global regions. The scores given in the figure are relative ratios compared to that of the Finnish group. **b**, Violin plot showing IBD scores in 29 tribal groups and 25 non-tribal groups consisting of 293 and 336 samples, respectively. The centre line indicates the median; box limits show 1.5× the interquartile range.

unique to our dataset ($n = 8,799$; Fig. 4d), similar to the PTV data from ExAC²⁵ (67% singletons). A smaller number were homozygous and had been reported in gnomAD, dbSNP or 1000 Genomes Project ($n = 856$). In addition, within our dataset were 121 homozygous PTVs that have not previously been reported (Supplementary Table 5). These novel homozygous PTVs were mostly found in groups with high IBD scores such as the Jarawa and Onge from the Andaman Islands (Fig. 4e). The novel homozygous PTVs include an allele of the *ABCA7* gene, Q2010*, that is found in only the Aeta population (Fig. 4f). Heterozygosity for loss-of-function alleles of *ABCA7* has been shown to increase susceptibility to Alzheimer's disease in European populations⁴⁸.

Imputation panel

We carried out preliminary work to evaluate the utility of the pilot dataset for imputation. For this analysis, we downsampled whole-genome sequence data from South Asian, Southeast Asian and Northeast Asian population groups (see Supplementary Table 1a for samples included in each of these geographically defined sets) 30× to the genotypes represented on the Illumina Global Screening Array v1 genotyping array, and compared the imputation using either phase 3 of the 1000 Genomes Project or the GASP reference panels. We found, as described by Illumina, that imputation accuracy of the 1000 Genomes Project reference panel is consistently well below 90% for east Asian and south Asian samples whereas using the GASP reference panel we achieved accuracies ranging from 93 to 95%. To accelerate evaluation and broad utility, we have placed the data on the Michigan Imputation Server (<https://imputationserver.sph.umich.edu/index.html>).

Discussion

Understanding the genetic basis of human disease will benefit from an increase in the number and scale of disease-association studies that are carried out in Asian populations. In the pilot phase of the GenomeAsia project, the sample set that we analysed allowed us to address a wide range of questions regarding the history of specific Asian population

groups and to map out strategies for additional sequencing efforts. We plan for a staged and coordinated approach, to include the generation of genomic population-specific reference datasets and imputation panels, and use this approach for the production of custom SNP arrays as a catalyst for disease-association studies. This approach is particularly useful in founder populations, such as recent studies in the founder populations of Finland⁴⁹, as well as other populations. This will be particularly valuable in Asia^{14,50}, which has founder effects that have not only previously been demonstrated in isolated populations, but are also evident in major urban centres.

Analysis of the GASP dataset allows us to map out strategies for efforts focused on specific population centres in Asia as well as the generation of important tools that will increase our understanding of how genetic variants affect disease susceptibility and drug responses. The dataset improves the ability to filter out low-probability candidates for highly penetrant disorders, to identify putatively pathogenic variants that are found at high frequency in particular populations and improve the ability to infer pathogenicity of identified variants. The identification of novel homozygous PTVs in this study expands the catalogue of genes in which homozygous loss of function appears to be tolerated and, when combined with phenotype information, this will provide important biological insights into gene function. The ability to define gene function in humans through the study of the phenotypic effects of loss-of-function mutations is becoming an increasingly valuable approach⁵¹ and the study of additional variants and populations in which homozygosity occurs at high rates will add to the global resources for carrying out human knockout studies.

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-019-1793-z>.

Online content

1. Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* **538**, 161–164 (2016).
2. Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat. Genet.* **51**, 584–591 (2019).
3. The Genome of the Netherlands Consortium. Whole-genome sequence variation, population structure and demographic history of the Dutch population. *Nat. Genet.* **46**, 818–825 (2014).
4. The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
5. Gurdasani, D. et al. The African Genome Variation Project shapes medical genetics in Africa. *Nature* **517**, 327–332 (2015).
6. Nagasaki, M. et al. Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals. *Nat. Commun.* **6**, 8018 (2015).
7. Sudmant, P. H. et al. An integrated map of structural variation in 2,504 human genomes. *Nature* **526**, 75–81 (2015).
8. Mallick, S. et al. The Simons Genome Diversity Project: 300 genomes from 142 diverse populations. *Nature* **538**, 201–206 (2016).
9. Mitt, M. et al. Improved imputation accuracy of rare and low-frequency variants using population-specific high-coverage WGS-based imputation reference panel. *Eur. J. Hum. Genet.* **25**, 869–876 (2017).
10. Southam, L. et al. Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits. *Nat. Commun.* **8**, 15606 (2017).
11. Xue, Y. et al. Enrichment of low-frequency functional variants revealed by whole-genome sequencing of multiple isolated European populations. *Nat. Commun.* **8**, 15927 (2017).
12. Lencz, T. et al. High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. *Hum. Genet.* **137**, 343–355 (2018).
13. Ebenesersdóttir, S. S. et al. Ancient genomes from Iceland reveal the making of a human population. *Science* **360**, 1028–1032 (2018).
14. Njølstad, P. R. et al. Roadmap for a precision-medicine initiative in the Nordic region. *Nat. Genet.* **51**, 924–930 (2019).
15. Bentley, A. R., Callier, S. & Rotimi, C. The emergence of genomic research in Africa and new frameworks for equity in biomedical research. *Ethn. Dis.* **29**, 179–186 (2019).
16. Nagai, A. et al. Overview of the BioBank Japan Project: study design and profile. *J. Epidemiol.* **27**, S2–S8 (2017).
17. Chen, Z. et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. *Int. J. Epidemiol.* **40**, 1652–1666 (2011).
18. Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. *Nat. Genet.* **38**, 904–909 (2006).
19. Schiffels, S. & Durbin, R. Inferring human population size and separation history from multiple genome sequences. *Nat. Genet.* **46**, 919–925 (2014).
20. Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry in unrelated individuals. *Genome Res.* **19**, 1655–1664 (2009).
21. The HUGO Pan-Asian SNP Consortium. Mapping human genetic diversity in Asia. *Science* **326**, 1541–1545 (2009).
22. Aghakhanian, F. et al. Unravelling the genetic history of Negritos and indigenous populations of Southeast Asia. *Genome Biol. Evol.* **7**, 1206–1215 (2015).
23. Reich, D. et al. Denisova admixture and the first modern human dispersals into Southeast Asia and Oceania. *Am. J. Hum. Genet.* **89**, 516–528 (2011).
24. Mijares, A. S. B. The early Austronesian migration to Luzon: perspectives from the Peñablanca cave sites. *Bull. Indo-Pacific Prehist. Assoc.* **26**, 72–78 (2006).
25. Détroit, F. et al. A new species of *Homo* from the Late Pleistocene of the Philippines. *Nature* **568**, 181–186 (2019).
26. Sankararaman, S., Mallick, S., Patterson, N. & Reich, D. The combined landscape of Denisovan and Neanderthal ancestry in present-day humans. *Curr. Biol.* **26**, 1241–1247 (2016).
27. Reich, D., Thangaraj, K., Patterson, N., Price, A. L. & Singh, L. Reconstructing Indian population history. *Nature* **461**, 489–494 (2009).
28. Majumder, P. P. & Basu, A. A genomic view of the peopling and population structure of India. *Cold Spring Harb. Perspect. Biol.* **7**, a008540 (2015).
29. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291 (2016).
30. NHLBI GO Exome Sequencing Project (ESP). *Exome Variant Server*. <http://evs.washington.edu/EVS/> (version: ESP6500SI-V2) (2015).
31. Piton, A., Redin, C. & Mandel, J. L. XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. *Am. J. Hum. Genet.* **93**, 368–383 (2013).
32. Chapla, A. et al. Maturity onset diabetes of the young in India - a distinctive mutation pattern identified through targeted next-generation sequencing. *Clin. Endocrinol.* **82**, 533–542 (2015).
33. Mohan, V. et al. Comprehensive genomic analysis identifies pathogenic variants in Maturity-Onset Diabetes of the Young (MODY) patients in south India. *BMC Med Genet.* **19**, 22 (2018).
34. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res.* **29**, 308–311 (2001).
35. Moayyeri, A., Hammond, C. J., Hart, D. J. & Spector, T. D. The UK Adult Twin Registry (TwinsUK Resource). *Twin Res. Hum. Genet.* **16**, 144–149 (2013).
36. Roden, D. M. & George, A. L. Jr. The genetic basis of variability in drug responses. *Nat. Rev. Drug Discov.* **1**, 37–44 (2002).
37. Ashley, E. A. et al. Clinical assessment incorporating a personal genome. *Lancet* **375**, 1525–1535 (2010).
38. Johnson, J. A. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. *Clin. Pharmacol. Ther.* **90**, 625–629 (2011).
39. Karczewski, K. J., Daneshjou, R. & Altman, R. B. Chapter 7: Pharmacogenomics. *PLoS Comput. Biol.* **8**, e1002817 (2012).
40. Urban, T. J. & Goldstein, D. B. Pharmacogenetics at 50: genomic personalization comes of age. *Sci. Transl. Med.* **6**, 220ps1 (2014).
41. Johnson, J. A. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. *Clin. Pharmacol. Ther.* **102**, 397–404 (2017).
42. Locke, A. E. et al. Exome sequencing of Finnish isolates enhances rare-variant association power. *Nature* **572**, 323–328 (2019).
43. Strauss, K. A. & Puffenberger, E. G. Genetics, medicine, and the Plain people. *Annu. Rev. Genomics Hum. Genet.* **10**, 513–536 (2009).
44. Polvi, A. et al. The Finnish disease heritage database (FinDis) update—a database for the genes mutated in the Finnish disease heritage brought to the next-generation sequencing era. *Hum. Mutat.* **34**, 1458–1466 (2013).
45. Nakatsuka, N. et al. The promise of discovering population-specific disease-associated genes in South Asia. *Nat. Genet.* **49**, 1403–1407 (2017).
46. Cox, J. J. et al. An SCN9A channelopathy causes congenital inability to experience pain. *Nature* **444**, 894–898 (2006).
47. Saleheen, D. et al. Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. *Nature* **544**, 235–239 (2017).
48. Steinberg, S. et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. *Nat. Genet.* **47**, 445–447 (2015).
49. Chheda, H. et al. Whole-genome view of the consequences of a population bottleneck using 2926 genome sequences from Finland and United Kingdom. *Eur. J. Hum. Genet.* **25**, 477–484 (2017).
50. Lim, E. T. et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. *PLoS Genet.* **10**, e1004494 (2014).
51. Nomura, A. et al. Protein-Truncating variants at the cholesterol ester transfer protein gene and risk for coronary heart disease. *Circ. Res.* **121**, 81–88 (2017).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

GenomeAsia100K Consortium

Jeffrey D. Wall^{1,47}, Eric W. Stawiski^{2,3,44,47}, Aakrosh Ratan^{4,47}, Hie Lim Kim^{5,6,47}, Changhoon Kim^{8,47}, Ravi Gupta^{9,47}, Kushal Suryamohan², Elena S. Gusareva⁶, Rikky Wenang Purbojati⁶, Tushar Bhargale^{3,10}, Vadim Stepanov^{11,12,13}, Vladimir Kharkov^{11,12,13}, Markus S. Schröder², Vedam Ramprasad⁹, Jennifer Tom³, Steffen Durinck^{2,3}, Qixin Bei², Jiani Li², Joseph Guillory², Sameer Phalke⁹, Analabha Basu¹⁴, Jeremy Stinson², Sandhya Nair⁹, Sivasankar Malaichamy⁹, Nidhan K. Biswas¹⁴, John C. Chambers¹⁵, Keith C. Cheng¹⁶, Joyner T. George⁹, Seik Soon Khor¹⁷, Jong-Il Kim^{18,19}, Belong Cho²⁰, Ramesh Menon⁹, Thiramsetti Sattibabu⁹, Akshi Bassi⁹, Manjari Deshmukh⁹, Anjali Verma⁹, Vivek Gopalan⁹, Jong-Yeon Shin²¹, Mahesh Pratapneni²², Sam Santhosh⁹, Katsushi Tokunaga^{23,24}, Badrul M. Md-Zain²⁵, Kok Gan Chan²⁶, Madasamy Parani²⁷, Purushothaman Natarajan²⁷, Michael Hauser^{28,29}, R. Rand Allingham^{29,46}, Cecilia Santiago-Turla²⁹, Arkasubhra Ghosh³⁰, Santosh Gopi Krishna Gadde³⁰, Christian Fuchsberger^{31,32,33}, Lukas Forer³³, Sebastian Schoenherr³³, Herawati Sudoyo³⁴, J. Stephen Lansing³⁵, Jonathan Friedlaender³⁶, George Koki³⁷, Murray P. Cox³⁸, Michael Hammer³⁹, Tatiana Karafet³⁹, Khai C. Ang^{16,25}, Syed Q. Mehdi^{40,46}, Venkatesan Radha^{41,42}, Viswanathan Mohan^{41,42}, Partha P. Majumder^{14,43,47*}, Somasekar Seshagiri^{2,45,47*}, Jeong-Sun Seo^{8,21,47*}, Stephan C. Schuster^{6,47*} & Andrew S. Peterson^{2,44,47*}

¹Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA. ²Department of Molecular Biology, Genentech, South San Francisco, CA, USA. ³Department of Bioinformatics and Computational Biology, Genentech, South San Francisco, CA, USA. ⁴Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA. ⁵The Asian School of the Environment, Nanyang Technological University, Singapore, Singapore. ⁶Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore, Singapore. ⁷Bioinformatics Institute, Macrogen, Seoul, South Korea. ⁸Precision Medicine Center, Seoul National University Bundang Hospital, Gyeonggi-do, South Korea. ⁹MedGenome Labs, Bengaluru, India. ¹⁰Department of Human Genetics, Genentech, South San Francisco, CA, USA. ¹¹Institute of Medical Genetics, Tomsk National Medical Research Center, Tomsk, Russian Federation. ¹²Russian Academy of Sciences, Tomsk, Russian Federation. ¹³Tomsk State University, Tomsk, Russian Federation. ¹⁴National Institute of BioMedical Genomics, Netaji Subhas Sanatorium, Kalyani, India. ¹⁵Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. ¹⁶Department of Pathology and Jake Gittlen Laboratories for Cancer Research, Penn State College of Medicine, Hershey, PA, USA.

¹⁷Department of Human Genetics, University of Tokyo, Tokyo, Japan. ¹⁸Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, South Korea. ¹⁹Genomic Medicine Institute (GMI), Medical Research Center, Seoul National University, Seoul, South Korea. ²⁰Department of Family Medicine, Seoul National University Hospital, Seoul, South Korea. ²¹Precision Medicine Institute, Macrogen, Gyeonggi-do, South Korea. ²²Emerge Ventures, Singapore, Singapore. ²³Genome Medical Science Project, Toyama, Japan. ²⁴National Center Biobank Network (NCBN), National Center for Global Health and Medicine (NCGM), University of Tokyo, Tokyo, Japan. ²⁵School of Environment and Natural Resource Science, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, Bangi, Malaysia. ²⁶Division of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia. ²⁷Department of Genetic Engineering, SRM Institute of Science and Technology, Kattankulathur, India. ²⁸Department of Ophthalmology, Duke University Medical Center, Durham, NC, USA. ²⁹Department of Medicine, Duke University Medical Center, Durham, NC, USA. ³⁰GROW Research Laboratory, Narayana Nethralaya Foundation, Bengaluru, India. ³¹Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA. ³²Institute for Biomedicine, Eurac Research, Bolzano, Italy. ³³Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria. ³⁴Genome Diversity and Diseases Laboratory, Eijkman Institute for Molecular Biology, Jakarta, Indonesia. ³⁵Complexity Institute, Nanyang Technological University, Singapore, Singapore. ³⁶Anthropology Department, Temple University, Philadelphia, PA, USA. ³⁷Papua New Guinea Institute for Medical Research, Goroka, Papua New Guinea. ³⁸School of Fundamental Sciences, Massey University, Palmerston North, New Zealand. ³⁹Division of Biotechnology, University of Arizona, Tucson, AZ, USA. ⁴⁰Center for Human Genetics, Sindh Institute of Urology and Transplantation, Karachi, Pakistan. ⁴¹Madras Diabetes Research Foundation, Chennai, India. ⁴²Dr. Mohan's Diabetes Specialities Centre, Chennai, India. ⁴³Human Genetics Unit, Indian Statistical Institute, Kolkata, India. ⁴⁴Present address: Seven Rivers Genomic Medicines, A division of MedGenome, Foster City, CA, USA. ⁴⁵Present address: SciGenom Research Foundation, Chennai, Tamil Nadu, India. ⁴⁶Deceased: R. Rand Allingham, Syed Q. Mehdi. ⁴⁷These authors contributed equally: Jeffrey D. Wall, Eric Stawiski, Aakrosh Ratan, Hie Lim Kim, Changhoon Kim, Ravi Gupta, Partha P. Majumder, Somasekar Seshagiri, Jeong-Sun Seo, Stephan C. Schuster, Andrew S. Peterson. *e-mail: ppm1@nibmg.ac.in; sekar@sgrf.org; jeongsun@snu.ac.kr; stephan.c.schuster@gmail.com; peterson.andrew@genomeasia100k.org

Methods

Data reporting

No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to the allocation during analysis.

Samples

We accessed publicly available high-coverage, whole-genome FASTQ files from previous studies of human genetic variation^{52–55} and combined these with 1,267 high-coverage genomes generated as part of this project. Full details on the samples chosen for sequencing and the informed consent processes for these samples can be found in Supplementary Information 1. We restricted our analyses to genomes generated using Illumina short-read sequencing technology.

Whole-genome sequencing

Whole-genome sequencing libraries were prepared using standard protocols (Illumina) and sequenced on Illumina HiSeq 2500/4000 or X10 machines. We obtained paired-end (2×100 bp or 2×150 bp) for each sample.

Filtering, alignment and variant calling

We aligned the Illumina short-read sequences to the GRCh37+decoy reference genome with BWA-mem⁵⁶ using the default parameters. Putative PCR duplicates were flagged using SAMBLASTER⁵⁷. The SAM outputs were converted to BAM format, and sorted by chromosomal coordinates using Sambamba⁵⁸, and all BAM files for the same samples were merged.

The sex of the samples was inferred from the coverage of the autosomes and the sex chromosomes, and confirmed from the submitted metadata with the samples. All samples that had an average coverage less than 20-fold or for which we found a difference in the inferred and reported sex were removed from further analysis. We used verifyBamID⁵⁹ to identify contamination using the chip-free mode and samples for which swaps or contamination was identified were removed from subsequent analyses. A contamination level of 3% was used as a cut-off, and this left us with 1,739 samples that were used for all downstream analyses.

We identified the single-nucleotide substitutions and small indels variants in the 1,739 samples using the reference model (gVCF-based) workflow for joint analysis in GATK⁶⁰. Variants were called individually in each sample using the HaplotypeCaller in ‘ERC GVCF’ mode to produce a record of genotype likelihoods and annotations at each site in the genome. Multi-allelic variants are reported in the GenomeAsia browser but were not included in the analysis. A gVCF file was created for every sample, and a subsequent joint genotyping analysis of all gVCFs was done to identify the variants in the cohort. We followed the GATK-recommended best practices for variant recalibration to create a final VCF file and recalibrated the variants to select 99% of the true sites from the training set for VQSR⁶¹. The VCF files were zipped using bgzip and indexed using tabix.

Identification of first-degree relative pairs

Several of the reported analyses require filtering to remove related samples. We used KING⁶² to identify such first-degree relative pairs. We first used vcftools⁶³ and plink⁶⁴ to convert the VCF file into the required input format for KING. The estimated kinship coefficient was restricted to 0.177–0.354 as described in the KING manual to identify the first-degree relative pairs, and the results were confirmed from the submitted metadata. The number of unrelated samples by country-of-origin is shown in Supplementary Table 1.1.

Quantifying population structure and changes in population size

We restricted our attention to 7,966,132 autosomal markers (that is, SNPs) with MAF ≥ 0.01 and call rate $\geq 98\%$. In some analysis, severe linkage disequilibrium pruning was applied as follows: sliding windows of

size 50 (that is, the number of markers used for linkage disequilibrium testing at a time) and window increments of 5 markers; for any pair of SNPs in a window, the first marker of the pair was discarded if $r^2 > 0.2$. After linkage disequilibrium pruning, 1,089,227 SNPs were retained for analysis. All data-filtering procedures were conducted in PLINK v.1.9⁶⁴.

Analyses of population structure was performed using the quality-control-positive linkage-disequilibrium-pruned set of 1,089,227 autosomal SNPs. Principal component analysis (PCA)¹⁸ was conducted across all available populations in EIGENSTRAT v.6.1.4. Results were visualized in Tableau v.9.3. We applied unsupervised hierarchical clustering of individuals using the maximum likelihood method implemented in ADMIXTURE v.1.3.0²⁰ using default input parameters. The ‘-cv’ flag was adopted to perform the cross-validation procedure and to calculate the optimal k value.

We used MSMC⁵ to estimate changes in population size and split times. This analysis used two different phased genome datasets (using Shapeit v.2⁶⁵ and Eagle²⁶⁶). The details for the phasing are described in Supplementary Information 4. Chromosome 6 was excluded from the analysis owing to possible phasing errors in the HLA region. We used four haplotypes (two individual genomes) for estimating changes in population size in a population and eight haplotypes (two genomes from each of a pair of populations) for the estimation of population split times. We assumed a mutation rate of $\mu = 1.25 \times 10^{-8}$ per site per generation and an average generation time of 29 years, as in previous studies^{8,19}.

Comparison with 1000 Genomes Project genotype calls

We filtered the variant calls to include only biallelic SNPs with $<10\%$ missing genotype calls that were within the 1000 Genomes Project strict mask (available at ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/accessible_genome_masks/20141020_strict_mask.whole_genome.bed). Then, for each of the 119 overlapping samples considered individually, we calculated variant discordance rates for those filtered SNPs that (1) had a genotype call in both the 1000 Genomes Project data and the GAsP data; and (2) had a ‘variant’ call (that is, a non-homozygous reference genotype call) in at least one of the datasets. These discordance rates were then stratified by the estimated MAF in the GAsP dataset.

Patterns of allele sharing

We used a parsimony-based analysis of allele sharing⁵⁵ that focused on SNPs that were not present in sub-Saharan Africans or in archaic humans (further details are provided in Supplementary Information 8).

Archaic admixture

We used a method similar to the ‘enhanced’ D -statistic approach^{8,67} to estimate levels of Neanderthal and Denisovan ancestry in each non-African sample. The estimates were calibrated assuming 0% Denisovan ancestry in the British population, 4% Denisovan ancestry in the Papuan population and 2% Neanderthal ancestry in the British population (full details are provided in Supplementary Information 9).

Determination of high-quality variants for medically related analyses

High-quality variants were defined as variants that (1) had a read-depth ≥ 5 and genotype-quality ≥ 20 ; (2) were contained in the high-confidence regions as described by Genome in a Bottle (ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/release/NA12878_HG001/NISTv3.3.2/GRCh37/supplementaryFiles/HG001_GRCh37_GIAB_highconf_CG-IllFB-IIIgATKHC-Ion-10X-SOLID_CHROM1-X_v.3.3.2_highconf.bed) and (3) passed the gnomAD_Filter. Variant annotation was carried out using SnpEff⁶⁸ (v.4.1).

IBD scores

Groups with at least two samples were considered for analysis. We restricted our analysis to genomic regions with high-confidence calls

Article

and removed related samples based on reported relationship, kinship, PCA and IBD analyses. The scores given in the figure are relative ratios compared to that of the Finnish group.

PTVs

PTVs are defined as high-quality variants that were annotated as having a strong impact on the protein (such as frameshifts, essential splice sites or premature stop codons). We restricted calls to high-confidence regions determined by Genome in a Bottle as described above and filtered for high-confidence PTVs using the LOFTEE program⁶⁹. We used a similar strategy for additional filtering of variants as proposed previously⁴⁷ and flagged variants with ≤ 7 reads covering the variant site; $\leq 80\%$ of reads had the variant, were not in the bottom 1 percentile of phyloP or gerpRS⁶⁵ scores and for which the affected transcripts made up less than 50% of all expression as specified by GTEx.

Enriched medically relevant variants

We compared variant allele counts for Asian and Oceania samples from the GenomeAsia cohort to allele counts present in non-Asian gnomAD samples (European (non-Finnish), European (Finnish), Latino, African or other) for variants found in a set of 124 medically relevant genes. The genes used were 115 genes used for prenatal screening⁷⁰ as well as the cancer-associated genes *BRCA1*, *BRCA2*, *TP53*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *PMS1* and *PMS2A*. A Fisher's exact test was used to calculate variations that were significantly overrepresented in the GenomeAsia subsamples and corrected for multiple testing using the Bonferroni method. We further accessed variants for these genes that had not previously been reported. All variants were further filtered as being damaging as determined by having a high impact on the protein (stop codon, essential splice site or frameshift mutation) or were predicted to be damaging by the Polyphen2 program. A cumulative comparison of allele counts for all over-represented and novel variants was performed and compared to non-Asian gnomAD to calculate a *P* value, odds ratio and relative difference in cumulative allele frequency (GenomeAsia cumulative allele frequency minus gnomAD non-Asian allele frequency). Reported *P* values were corrected for multiple testing using the Bonferroni method.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Data availability

For each variant, summary data for genotype quality, allele depth and population-specific allele counts were calculated before removing all genotype data. This dataset is available without requirement for login or other form of restriction for browsing or for download at <https://browser.genomeasia100k.org>. Individual level VCF data files representing the 1,180 newly sequenced genomes from individuals of 74 population groups are freely available to any qualified investigator without restriction. Chinese samples sequenced were from Corriell cell lines and are not subject to Chinese government regulation. The data are also available from the European Genome Archive (EGA) under accession number EGAS00001002921. The procedure for accessing individual level data are as follows: access forms can be obtained from the GenomeAsia website (<https://browser.genomeasia100k.org>), and once filled out and sent to dataaccess@genomeasia100k.org the request will undergo administrative review and instructions for downloading the data will be returned to the requestor. Access to individual level data from Malaysian samples are subject to additional restrictions. The complete dataset of sequences of unrelated individuals (1,667 samples) has been phased and can be used for imputation through the Michigan Imputation Server (<https://imputationserver.sph.umich.edu/index.html>). The goal of the GenomeAsia100K consortium is to

facilitate and accelerate genetic studies in Asian populations by coordinating sequencing efforts among its members. To achieve this goal, we are committed to continuing to make data publicly available and accessible. As data are contributed to the consortium by individual members, it will be made immediately available in summary form or as imputation reference panels where appropriate. Data will be made available in individual form wherever possible and not limited by the bounds of informed consent, national privacy laws and regulations, or other external restrictions that may apply.

52. Wong, L. P. et al. Deep whole-genome sequencing of 100 southeast Asian Malays. *Am. J. Hum. Genet.* **92**, 52–66 (2013).
53. Wong, L. P. et al. Insights into the genetic structure and diversity of 38 South Asian Indians from deep whole-genome sequencing. *PLoS Genet.* **10**, e1004377 (2014).
54. Vernot, B. et al. Excavating Neanderthal and Denisovan DNA from the genomes of Melanesian individuals. *Science* **352**, 235–239 (2016).
55. Wall, J. D. Inferring human demographic histories of non-African populations from patterns of allele sharing. *Am. J. Hum. Genet.* **100**, 766–772 (2017).
56. Aaboud, M. et al. Combination of the searches for pair-produced vectorlike partners of the third-generation quarks at $\sqrt{s} = 13$ TeV with the ATLAS detector. *Phys. Rev. Lett.* **121**, 211801 (2018).
57. Faust, G. G. & Hall, I. M. SAMBLASTER: fast duplicate marking and structural variant read extraction. *Bioinformatics* **30**, 2503–2505 (2014).
58. Tarasov, A., Vilella, A. J., Cuppen, E., Nijman, I. J. & Prins, P. Sambamba: fast processing of NGS alignment formats. *Bioinformatics* **31**, 2032–2034 (2015).
59. Jun, G. et al. Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data. *Am. J. Hum. Genet.* **91**, 839–848 (2012).
60. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat. Genet.* **43**, 491–498 (2011).
61. Van der Auwera, G. A. et al. From FastQ data to high-confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr. Protoc. Bioinformatics* **43**, 11.10.1–11.10.33 (2013).
62. Manichaikul, A. et al. Robust relationship inference in genome-wide association studies. *Bioinformatics* **26**, 2867–2873 (2010).
63. Danecek, P. et al. The variant call format and VCFtools. *Bioinformatics* **27**, 2156–2158 (2011).
64. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
65. Delaneau, O., Zagury, J. F. & Marchini, J. Improved whole-chromosome phasing for disease and population genetic studies. *Nat. Methods* **10**, 5–6 (2013).
66. Loh, P. R. et al. Reference-based phasing using the Haplotype Reference Consortium panel. *Nat. Genet.* **48**, 1443–1448 (2016).
67. Prüfer, K. et al. The complete genome sequence of a Neanderthal from the Altai Mountains. *Nature* **505**, 43–49 (2014).
68. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain *w1118; iso-2; iso-3*. *Fly* **6**, 80–92 (2012).
69. MacArthur, D. G. et al. A systematic survey of loss-of-function variants in human protein-coding genes. *Science* **335**, 823–828 (2012).
70. Haque, I. S. et al. Modeled fetal risk of genetic diseases identified by expanded carrier screening. *J. Am. Med. Assoc.* **316**, 734–742 (2016).

Acknowledgements We thank the many individuals from all across Asia who gave blood samples for scientific research and the many individuals who supported the sample collection. The computational work for this article was partially performed on resources of the National Supercomputing Centre, Singapore (<https://www.nsc.sg>).

Author contributions J.D.W., E.W.S., A.R., A. Basu, K.C.C., M. Pratapneni, S. Santhosh, H.S., J.S.L., P.P.M., J.-S.S., S.C.S., S. Seshagiri and A.S.P. designed the study. S. Seshagiri, A.S.P., S.C.S., V. Ramprasada, J.G.J.S. and J.T.G. produced the sequencing data. S. Seshagiri, S.P., J.D.W., E.W.S., R.W.P. and A.R. carried out the data processing and quality control. P.P.M., K.C.C., J.S.L., J.-S.S., S.N., S.M., J.T.G., S.S.K., S.G.K.G., K.G.C., J.-I.K., C.K., B.C., B.M.M.-Z., J.-Y.S., K.T., M. Parani, P.N., C.S.-T., M. Hauser, R.R.A., A.G., M.P.C., J.F., M. Hammer, T.K., K.C.A., S.Q.M., V.M., V. Radha and G.K. coordinated, collected and/or provided samples. C.F., L.F. and S. Schoenherr generated the imputation server. P.P.M., S. Seshagiri, J.D.W., E.W.S., A.R., A.S.P., H.L.K., R.G., K.S., E.S.G., T.B., V.K., V.S., M.S.S., J.T., S.D., Q.B., J.L., N.K.B., R.M., T.S., A.V., V.G., A. Bassi, A. Basu, C.K. and M.D. carried out analyses. J.D.W., S. Seshagiri, E.W.S. and A.S.P. wrote the paper.

Competing interests A.S.P., E.W.S., S. Seshagiri, T.B., J.T.G., J.T., J. Stinson, Q.B., M.S.S., S.D. and K.S. were employees of Genentech at the time this work was carried out. S. Santhosh, A.V., M. Pratapneni, V. Ramprasada, S.P., R.M., R.G., S.N., S.M., T.S., V.G., J.T.G., M.D. and S.P. are employees of and/or have equity in MedGenome. C.K., J.-S.S. and J.-Y.S. are employees of Macrogen.


Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41586-019-1793-z>.

Correspondence and requests for materials should be addressed to S. Seshagiri, J.-S.S., S. Schuster and A.S.P.


Peer review information Nature thanks Rasmus Nielsen and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at <http://www.nature.com/reprints>.



Extended Data Fig. 1 | Diversity and divergence times of GASp samples.
a, PCA plot of study samples. Africa (AFR), $n = 102$; West Eurasia (WER), $n = 111$; South Asia (SAS), $n = 642$; Southeast Asia (SEA), $n = 162$; Oceania (OCE), $n = 68$; Northeast Asia (NEA), $n = 346$; Americas (AMR), $n = 26$. The samples included in each of these geographically defined groups are described in Supplementary

Table 1a. **b**, MSMC cross-coalescence rates showing divergence time estimates between different groups. The point estimate of the date was given at which 25%, 50% and 75% of lineages in the pair of populations have coalesced into a common ancestral population.



Extended Data Fig. 2 | Characteristics of GAsP SNPs and indels.
a, b, Comparison of all GAsP variants (**a**) or coding variants (**b**) with gnomAD, ExAC, 1000 Genomes, ESP and dbSNP data as a function of the MAF within the

GAsP dataset. **c, d**, The number and lengths of small indels in the genome (**c**) or coding regions (**d**). **e–h**, Proportion of non-coding (**e, g**) or coding (**f, h**) indels that were singletons (**e, f**) or rare (allele frequency of <0.1%; **g, h**).

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- ☐ ☒ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- ☐ ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- ☐ ☒ The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- ☐ ☒ A description of all covariates tested
- ☐ ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- ☐ ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- ☐ ☒ For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- ☐ ☒ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- ☐ ☒ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- ☐ ☒ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

no software was used

Data analysis

BWA version 0.7.13 (<https://github.com/lh3/bwa>);
 SAMBLASTER version 0.1.22 (<https://github.com/GregoryFaust/samblaster>) Sambamba version 0.6.1 (<https://github.com/lomereiter/sambamba>) BAMreport version 0.0.2; (<https://github.com/aakrosh/BAMreport>) verifyBamID version 1.1.3 (<http://genome.sph.umich.edu/wiki/VerifyBamID>); GATK version 3.5 (<https://software.broadinstitute.org/gatk/>);
 vcfnano version 0.1.0-dev (<https://github.com/brentp/vcfnano>);
 htlib version 1.3.1-64-g74bcfd7 (<https://github.com/samtools/htlib>); vcftools version 0.1.14 (<https://vcftools.github.io/index.html>);
 plink version 1.90b3.40 (<http://zzz.bwh.harvard.edu/plink/>); king version 1.4 (<http://people.virginia.edu/~wc9c/KING/>); rtg-tools version 3.7 (<https://github.com/RealTimeGenomics/rtg-tools>);
 Shapeit v2 (Delaneau et al, 2012);
 ex- tractPIRs (Delaneau et al, 2013);
 Eagle2 algorithm (Loh et al. 2016), version 2.3;
 generate_multihetsep.py, downloaded from <https://github.com/stschiff/msmc-tools>;
 Admixture v.1.3.0 (Alexander et al, 2009);
 EIGENSTRAT v.6.1.4 (Price et al, 2006);
 Selscan v. 1.1.0 (Szpiech and Hernandez 2014);
 BEAST v.1.8.4 (Drummond et al. 2012);
 PLINK v1.9

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

For each variant, summary data for genotype quality, allele depth and population specific allele counts were calculated before removing all genotype data. This data set is available without requirement for login or other form of restriction for browsing or for download at (<https://browser.genomeasia100k.org>). Individual level VCF data files representing 1,180 newly sequenced genomes from individuals in 74 population groups are freely available to any qualified investigator without restriction. Chinese samples sequenced were from Coriell cell lines and are not subject to the Chinese regulation. The data are available from the European Genome Archive (EGA) under accession number EGAS00001002921.

The procedure for accessing individual level data is as follows:

Access forms obtained from the GenomeAsia website (<https://browser.genomeasia100k.org>), once filled out and returned to dataaccess@genomeasia100k.org will undergo administrative review and instructions for download will be returned to the requestor. Access to individual level data from Malaysian samples are subject to additional restrictions.

The complete data set of sequences of unrelated individuals (1,667 samples) has been phased and can be used for imputation through the Michigan Imputation Server (<https://imputationserver.sph.umich.edu/index.html>)

The goal of the GenomeAsia100K consortium is to facilitate and accelerate genetic studies in Asian populations by coordinating sequencing efforts amongst its members. To achieve this goal we are committed to continuing to make data publicly available and accessible. As data is contributed to the consortium by individual members it will be made immediately available in summary form or as imputation reference panels where appropriate. Data will be made available in individual form wherever possible and not limited by the bounds of informed consent, national privacy laws and regulations, or other external restrictions that may apply.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No statistical methods were used to predetermine sample size. and the investigators were not blinded to the allocation during analysis.
Data exclusions	data was not excluded unless it failed essential QC metrics
Replication	results were not externally replicated
Randomization	The experiments were not randomized.
Blinding	Investigators were not blinded to the allocation during analysis.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	200 populations groups were included in our study and study participants included equal numbers of both genders
Recruitment	participants were recruited based on self and external identification as member of a specific population groups
Ethics oversight	Nanyang Technological University institutional review board (IRB- 2014-12-011)

Note that full information on the approval of the study protocol must also be provided in the manuscript.